First Wave BioPharma Files 8-K with Corporate Updates
Ticker: GRDX · Form: 8-K · Filed: May 16, 2024 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | First Wave Biopharma, Inc. (GRDX) |
| Form Type | 8-K |
| Filed Date | May 16, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, filing, regulatory
TL;DR
FWBP filed an 8-K on 5/16 for 5/15 events - corporate changes, Reg FD, exhibits. Check for details.
AI Summary
First Wave BioPharma, Inc. (formerly AzurRx BioPharma, Inc.) filed an 8-K on May 16, 2024, reporting events as of May 15, 2024. The filing indicates changes to its Articles of Incorporation or Bylaws, a Regulation FD disclosure, and other events, along with financial statements and exhibits. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This 8-K filing signals potential corporate restructuring or significant operational updates for First Wave BioPharma, which could impact its stock performance and investor outlook.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can lead to significant stock price volatility, especially when related to corporate structure or regulatory disclosures.
Key Players & Entities
- First Wave BioPharma, Inc. (company) — Registrant
- AzurRx BioPharma, Inc. (company) — Former company name
- BioPharma d'Azur, Inc. (company) — Former company name
- May 15, 2024 (date) — Date of earliest event reported
- May 16, 2024 (date) — Filing date
FAQ
What specific changes were made to First Wave BioPharma's Articles of Incorporation or Bylaws?
The filing indicates "Amendments to Articles of Incorporation or Bylaws" as an item of disclosure, but the specific details of these amendments are not provided in the provided text snippet.
What is the nature of the Regulation FD Disclosure mentioned in the filing?
The filing lists "Regulation FD Disclosure" as an item, but the specific content of this disclosure is not detailed in the provided text.
What are the "Other Events" reported by First Wave BioPharma?
The filing notes "Other Events" as a category of disclosure, but the specific events are not enumerated in the provided text.
When did First Wave BioPharma change its name from AzurRx BioPharma, Inc.?
The filing states the date of name change from AzurRx BioPharma, Inc. to First Wave BioPharma, Inc. was November 3, 2014.
What is the IRS Employer Identification Number for First Wave BioPharma, Inc.?
The IRS Employer Identification Number for First Wave BioPharma, Inc. is 46-4993860.
Filing Stats: 617 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-05-16 07:16:09
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share FWBI Nasdaq Capital Mark
Filing Documents
- tm2414628d1_8k.htm (8-K) — 30KB
- tm2414628d1_ex3-1.htm (EX-3.1) — 3KB
- tm2414628d1_ex99-1.htm (EX-99.1) — 15KB
- tm2414628d1_ex3-1img001.jpg (GRAPHIC) — 113KB
- tm2414628d1_ex3-1img002.jpg (GRAPHIC) — 136KB
- tm2414628d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- 0001104659-24-062263.txt ( ) — 572KB
- fwbi-20240515.xsd (EX-101.SCH) — 3KB
- fwbi-20240515_lab.xml (EX-101.LAB) — 33KB
- fwbi-20240515_pre.xml (EX-101.PRE) — 22KB
- tm2414628d1_8k_htm.xml (XML) — 4KB
03
Item 5.03 Amendments to Articles of Incorporation or Bylaws On May 15, 2024, First Wave BioPharma, Inc. (the "Company") filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to change its corporate name from "First Wave BioPharma, Inc." to "Entero Therapeutics, Inc." (the "Name Change Amendment"). Pursuant ot the Name Change Amendment, this name change is effective as of May 17, 2024. The Name Change Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.
01
Item 7.01 Regulation FD Disclosure. The information contained in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference.
01
Item 8.01 Other Events. On May 16, 2024, the Company issued a press release announcing the Name Change Amendment (the "Press Release"). As described in the Press Release, in connection with the Name Change Amendment, the Company's ticker symbol for its common stock, par valule $0.0001 per share, listed on the Nasdaq Capital Market, will be changed as of market open on May 17, 2024, from "FWBI" to "ENTO". A copy of this Press Release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . The following Exhibits are being filed with this Current Report on Form 8-K. Exhibit No. Description 3.1 Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation 99.1 Press Release, dated May 16, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entero Therapeutics, Inc. May 16, 2024 By: /s/ James Sapirstein Name: James Sapirstein Title: Chief Executive Officer